Pill Or Pin: The Race To Capture The GLP-1 Market

The GLP-1 market is becoming even more accessible—here's what that means for patients, providers, and anyone paying attention to one of the biggest shifts in healthcare today.

Weight-loss medicine is changing faster than at any point in modern history. Wegovy is breaking prescription records. Retatrutide, a next-generation injectable, is yielding results that rival bariatric surgery. And a market that barely existed five years ago is now projected to reach $268 billion by 2030.

Not All "GLP-1 Drugs" Work The Same Way

The media uses the term "GLP-1" as a catch-all, but today's obesity medicines span three distinct generations of science. Each mimics hormones and activates receptors to trigger weight loss in a way that previous medications and even surgeries have not been able to produce.

Dr. Peter Balazs, a hormone and weight-loss specialist in New York, argues the terminology itself needs to catch up to science. 

"The treatment goal is no longer just BMI reduction, but total cardiometabolic risk mitigation, with effects now documented across the liver, heart, kidneys, and vasculature. We should label these drugs as multi-system metabolic modulators — not simple weight loss drugs." - Dr. Peter Balazs, Hormone & Weight Loss Specialist.

The Injectable Pipeline Isn't Standing Still

Injectables still lead on raw efficacy. Zepbound (tirzepatide), a dual GLP-1/GIP agonist, currently leads the approved market with an average weight loss of around 22.5%.

In the pipeline, Eli Lilly's retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon, reported up to 29% weight loss in Phase 3 data. These numbers rival those of bariatric surgery weight loss.

Novo Nordisk's CagriSema has an FDA application pending, and Amgen's monthly injectable MariTide is in Phase 3. The injectable pipeline is not standing still.

For clinicians, expanding GLP-1 options is welcome, but it raises new questions. As one Medscape physician panel put it:

"Obesity isn't one-size-fits-all, and treatment can't be either. With a broader range of options — different mechanisms, side effect profiles, and dosing — we'll be able to better match the right treatment to the right person." - Medscape Physician Panel.

The Pill Changes Who Gets Treated

The FDA's approval of the first oral GLP-1 pill for obesity in December 2025 was less a clinical milestone than a behavioral one.

Within six weeks of launch, 57,000 Americans had filled a prescription for the Wegovy pill, one of the fastest drug launches ever recorded, with roughly 9 in 10 paying cash out of pocket.

Goldman Sachs Research forecasts that oral pills will capture roughly 25% of the anti-obesity medication market by the end of the decade.

Novo Nordisk CEO Mike Doustdar framed the pill's significance not as a product launch, but as a market expansion event:

"There is a huge number of patients who are simply not interested in losing weight at the cost of injecting themselves. The pill changes who we can reach." - Mike Doustdar, CEO, Novo Nordisk

Meanwhile, Eli Lilly's orforglipron, an oral small molecule with no food restrictions at dosing, is expected to receive FDA clearance within weeks, and Structure Therapeutics reported 16.3% weight loss for its oral candidate aleniglipron in Phase 2, the highest for any oral GLP-1 drug to date. The oral race is just beginning.

So, Which Is Better: Pill Or Pin?

• For maximum weight loss:  injectables—especially dual agonists like Zepbound—still lead, with triple agonist retatrutide showing even more promise. 

• For accessibility and ease:  oral GLP-1 drugs are rapidly closing the gap and reaching patients who never would have started a weekly injection. The most likely future is both, used differently: injections for intensive treatment, pills for everyday management and maintenance.

It is estimated that upwards of 30 million Americans will be on GLP-1 treatment by 2030—up from around 20 million today.

With Medicare coverage expanding, cash prices falling, and new drugs arriving quarterly, these medications will drive more than just weight loss. With these medication options, we should expect to see a reduction in diseases such as diabetes, cardiovascular diseases, and diseases associated with inflammation, such as arthritis.

How Market Research Can Help

For market researchers, this landscape is both an opportunity and a warning. The GLP-1 category is evolving so rapidly—with new mechanisms, new delivery formats, new entrants, and shifting policy—that yesterday's competitive analysis can be outdated within a single quarter.

IQVIA notes that if 2024 was a transition year and 2025 was consolidation, 2026 is shaping up to be the year of acceleration, with oral GLP-1s, patent expirations, and Medicare coverage all converging at once.

There are a few strategic questions that matter most: Which patient segments remain untreated and why? How will oral uptake reshape prescribing behavior among physicians? What does a generic entry in markets like China, India, and Brazil mean for global pricing strategy? And how will adjacent industries—like medtech, food, and beverage—adapt as patient behavior shifts at scale?

The Bottom Line

The GLP-1 market encompasses several races happening simultaneously: injectable vs. oral, efficacy vs. convenience, branded vs. generic, and U.S. vs. global. 

The organizations that will lead in this space are those investing now in primary research, looking at real-world evidence, and patient behavior data, not those waiting for the competitive picture to settle. It won't.

Ready to learn how your organization can get ahead in the GLP-1 market? Contact MDRG today. 

References